Live Analyst Rating Changes 1527 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Christophe dombu
KEPL
Christophe dombu
Kepler Capital
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-5.2%
Average Return
0 of 1 calls profitable · -20.6% vs benchmark
📈 Across the calls we could measure, roughly 0% of Christophe dombu's ratings turned a profit when each position was held for 1 year — averaging -5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

82 Buy 3 Hold 9 Sell
Christophe's Stock Coverage 14 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
SNN
Smith & Nephew Snats
 Jun 04, 2026 HOLD Buy
+11.8% avg upside
14 analysts
 — ·
GB:0QBO
Coloplast A/S
 May 20, 2026 BUY Buy
+86.5% avg upside
16 analysts
$482.00
27.66% Upside
 ·
NL:LKFT
Galapagos
 May 07, 2026 SELL Sell
+113.0% avg upside
16 analysts
$23.50
4.37% Downside
 ·
GB:0QW0
arGEN X
 May 07, 2026 BUY Strong Buy
-22.9% avg upside
24 analysts
$810.00
5.27% Upside
 ·
GB:SN
Smith & Nephew
 May 06, 2026 BUY Strong Buy
+1314.8% avg upside
15 analysts
$1462.00
29.86% Upside
 ·
FR:VIRP
Virbac SA
 Apr 17, 2026 BUY Buy
+5.2% avg upside
3 analysts
$415.00
21.86% Upside
 ·
NL:ONWD
Onward Medical N.V.
 Apr 16, 2026 BUY Strong Buy
1 analyst
$9.70
 ·
CH:KURN
Kuros Biosciences
 Apr 14, 2026 BUY Strong Buy
+105.4% avg upside
1 analyst
$38.00
105.37% Upside
 ·
CH:BSLN
Basilea Pharmaceutica
 Apr 13, 2026 BUY Strong Buy
+42.6% avg upside
6 analysts
$70.00
36.41% Upside
 ·
GB:0HNZ
Fagron SA
 Apr 09, 2026 BUY Buy
-7.9% avg upside
5 analysts
$27.50
14.38% Upside
 ·
FR:MAAT
MaaT Pharma
 Mar 31, 2026 BUY Strong Buy
+477.9% avg upside
2 analysts
$17.00
495.38% Upside
 ·
DE:52U
Hyloris Pharmaceuticals SA
 Mar 26, 2026 BUY Strong Buy
+250.0% avg upside
2 analysts
$14.30
219.83% Upside
 ·
NYXH
Nyxoah
 Mar 20, 2026 BUY Strong Buy
+851.5% avg upside
12 analysts
$12.05
653.21% Upside
 -5.2%
FR:ALVIO
Valerio Therapeutics
 Feb 07, 2025 SELL Buy
+127.0% avg upside
3 analysts
$0.01
95.19% Downside
 ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Christophe dombu — Frequently Asked Questions
How accurate are Christophe dombu's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Christophe's ratings were profitable over a one-year hold, with an average return of -5.2% per rating, or -20.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Christophe ranked on 13Foresight?
Christophe dombu is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Christophe cover?
Christophe most recently has ratings on SNN, GB:0QBO, NL:LKFT, GB:0QW0, GB:SN, FR:VIRP, NL:ONWD, CH:KURN, CH:BSLN, GB:0HNZ, FR:MAAT, DE:52U and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.